MedTrace Logo

IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)

NCT05516797 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2025-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or fingerstick blood glucose monitoring (BGM) in people with Type 2 diabetes who participate in the Virta Treatment program.

Conditions

Interventions

DEVICE

Continuous Glucose Monitoring (CGM)

Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring

Sponsors & Collaborators

  • Virta Health

    collaborator INDUSTRY

  • Abbott Diabetes Care

    collaborator INDUSTRY

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Holly Willis, PhD · HealthPartners Institute dba International Diabetes Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-22
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516797 on ClinicalTrials.gov